Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Validate Reagents on Tecan, BMG Labtech Platforms

NEW YORK (GenomeWeb News) — Invitrogen said Tuesday that it has inked two new agreements, one with Tecan and another with BMG Labtech, to study and validate its reagents with the companies’ microplate instruments.
Under the terms of both of the agreements, announced separately, Invitrogen will work with the companies to develop and promote joint applications to market to pharmaceutical companies.
In the agreement with Tecan, Invitrogen will validate the compatibility of its reagents with Tecan’s microplate detection tools.
Specifically, the companies will validate Invitrogen’s drug discovery reagents on the Tecan Infinite series readers, and on assay systems for key target classes, including Invitrogen’s LanthaScreen TR-FRET for protein kinases, the GeneBLAzer reporter-gene technology for G protein-coupled receptors, and the Adapta assay system for lipid kinases.
Under the BMG Labtech agreement, Invitrogen will test its reagents with certain of the company’s readers, as well as its PHERAstar and Omega series instruments.
This collaboration will also focus on Invitrogen’s LanthaScreen TR-FRET, GeneBLAzer, and Adapta assays, as well as the PolarScreen FP technology for nuclear receptors.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.